Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Stathmi, Inc.

2 abstracts

Abstract
PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC).
Org: Stathmi, Inc.,
Abstract
Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer.
Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Medicine, Section of Hematology & Oncology, University of Chicago Medical Center, Dana-Farber Cancer Institute, Department of Internal Medicine, Seoul National University Bundang Hospital,